ML 297 is a selective Kir3.1/3.2 (GIRK1/2) channel activator (IC50 values are 160, 887 and 914 nM for GIRK1/2, GIRK1/4 and GIRK1/3 respectively). ML 297 exhibits no effect on GIRK2, GIRK2/3, Kir2.1 and Kv7.4 channels, and has minimal effect on a panel of other ion channels, receptors and transporters.

Ropivacaine (LEA-103 HCl) is a local anaesthetic drug belonging to the amino amide group.

Compound 2a, identified as TWIK-1/TREK-1-IN-1, acts as an inhibitor of the TREK-1, a two-pore domain potassium channel (K2p) that forms TREK-1 homodimers and TWIK-1/TREK-1 heterodimers, both significant for its role as an antidepressant target. Furthermore, TWIK-1/TREK-1-IN-3, a related compound, selectively inhibits these channels with IC50 values of 9.36 μM for TREK-1 homodimers and 14.6 μM for TWIK-1/TREK-1 heterodimers, demonstrating antidepressant-like effects [1].

Margatoxin TFA, an alpha-KTx scorpion toxin isolated from Centruroides margaritatus venom, is a 39-amino-acid peptide that serves as a high-affinity inhibitor of Kv1.3 (Kd = 11.7 pM). It also inhibits Kv1.2 (Kd = 6.4 pM) and Kv1.1 (Kd = 4.2 nM), making it a valuable tool for ion channel research [1] [2].

Stromatoxin 1, a peptide isolated from tarantulas, acts as an inhibitor of various potassium channels, including K(V)2.1, K(V)2.2, K(V)4.2, and K(V)2.1/9.3. It selectively targets K(V)2.1 and K(V)2.2 channel subunits, which are crucial in counteracting myogenic and neurogenic contractions of rat urinary bladder smooth muscle (UBSM) [1].